{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:47:41Z","timestamp":1791920861058,"version":"4.3.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81372134"],"award-info":[{"award-number":["81372134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81641012"],"award-info":[{"award-number":["81641012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00430-018-0570-1","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T10:38:07Z","timestamp":1541068687000},"page":"573-583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis"],"prefix":"10.1007","volume":"208","author":[{"given":"Huali","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runliang","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"issue":"5","key":"570_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"12","key":"570_CR2","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nrc.2016.92","volume":"16","author":"LS Young","year":"2016","unstructured":"Young LS, Yap LF, Murray PG (2016) Epstein\u2013Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer 16(12):789\u2013802. https:\/\/doi.org\/10.1038\/nrc.2016.92","journal-title":"Nat Rev Cancer"},{"issue":"Pt 1","key":"570_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-3-319-22822-8_11","volume":"390","author":"R Rochford","year":"2015","unstructured":"Rochford R, Moormann AM (2015) Burkitt\u2019s Lymphoma. Curr Top Microbiol Immunol 390(Pt 1):267\u2013285. https:\/\/doi.org\/10.1007\/978-3-319-22822-8_11","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"570_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2559.2010.03705.x","volume":"58","author":"K Farrell","year":"2011","unstructured":"Farrell K, Jarrett RF (2011) The molecular pathogenesis of Hodgkin lymphoma. Histopathology 58(1):15\u201325. https:\/\/doi.org\/10.1111\/j.1365-2559.2010.03705.x","journal-title":"Histopathology"},{"issue":"20","key":"570_CR5","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","volume":"125","author":"A Arvey","year":"2015","unstructured":"Arvey A, Ojesina AI, Pedamallu CS, Ballon G, Jung J, Duke F et al (2015) The tumor virus landscape of AIDs-related lymphomas. Blood 125(20):e14\u2013e22","journal-title":"Blood"},{"key":"570_CR6","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","volume":"2","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S (2016) Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2:15088. https:\/\/doi.org\/10.1038\/nrdp.2015.88","journal-title":"Nat Rev Dis Primers"},{"issue":"Pt 1","key":"570_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/978-3-319-22822-8_13","volume":"390","author":"JA Healy","year":"2015","unstructured":"Healy JA, Dave SS (2015) The role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr Top Microbiol Immunol 390(Pt 1):315\u2013337. https:\/\/doi.org\/10.1007\/978-3-319-22822-8_13","journal-title":"Curr Top Microbiol Immunol"},{"issue":"8","key":"570_CR8","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s00277-018-3313-x","volume":"97","author":"J Cho","year":"2018","unstructured":"Cho J, Kim SJ, Park S, Yoo KH, Ki CS, Ko Y, Kim WS (2018) Significance of circulating Epstein\u2013Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. Ann Hematol 97(8):1427\u20131436. https:\/\/doi.org\/10.1007\/s00277-018-3313-x","journal-title":"Ann Hematol"},{"key":"570_CR9","doi-asserted-by":"publisher","first-page":"7349268","DOI":"10.1155\/2017\/7349268","volume":"2017","author":"SY Teow","year":"2017","unstructured":"Teow SY, Yap HY, Peh SC (2017) Epstein\u2013Barr virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment. J Pathog 2017:7349268. https:\/\/doi.org\/10.1155\/2017\/7349268","journal-title":"J Pathog"},{"issue":"20","key":"570_CR10","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1097\/MD.0000000000000792","volume":"94","author":"XZ Chen","year":"2015","unstructured":"Chen XZ, Chen H, Castro FA, Hu JK, Brenner H (2015) Epstein\u2013Barr virus infection and gastric cancer: a systematic review. Medicine 94(20):e792. https:\/\/doi.org\/10.1097\/MD.0000000000000792","journal-title":"Medicine"},{"key":"570_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1743-422X-9-77","volume":"9","author":"Y Dai","year":"2012","unstructured":"Dai Y, Tang Y, He F, Zhang Y, Cheng A, Gan R, Wu Y (2012) Screening and functional analysis of differentially expressed genes in EBV-transformed lymphoblasts. Virol J 9:77\u201381. https:\/\/doi.org\/10.1186\/1743-422X-9-77","journal-title":"Virol J"},{"issue":"2","key":"570_CR12","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.3892\/mmr.2014.2313","volume":"10","author":"Y Tang","year":"2014","unstructured":"Tang Y, Luo C, Cheng A, Lu S, Xu J, Fu T, Gan R (2014) Expression of latent membrane proteins in Epstein Barr virus-transformed lymphocytes in vitro. Mol Med Rep 10(2):1117\u20131121. https:\/\/doi.org\/10.3892\/mmr.2014.2313","journal-title":"Mol Med Rep"},{"issue":"9","key":"570_CR13","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1349-7006.2003.tb01521.x","volume":"94","author":"R Gan","year":"2003","unstructured":"Gan R, Yin Z, Liu T, Wang L, Tang Y, Song Y (2003) Cyclosporine A effectively inhibits graft-versus-host disease during development of Epstein\u2013Barr virus-infected human B cell lymphoma in SCID mouse. Cancer Sci 94(9):796\u2013801. https:\/\/doi.org\/10.1111\/j.1349-7006.2003.tb01521.x","journal-title":"Cancer Sci"},{"issue":"10","key":"570_CR14","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1002\/jmv.24526","volume":"88","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Peng X, Tang Y, Gan X, Wang C, Xie L et al (2016) Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein\u2013Barr virus-associated lymphomas. J Med Virol 88(10):1804\u20131813. https:\/\/doi.org\/10.1002\/jmv.24526","journal-title":"J Med Virol"},{"issue":"10","key":"570_CR15","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1158\/1541-7786.MCR-11-0145","volume":"9","author":"A Leo De","year":"2011","unstructured":"De Leo A, Arena G, Stecca C, Raciti M, Mattia E (2011) Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt\u2019s lymphoma cells depending on viral latency program. Mol Cancer Res 9(10):1346\u20131355. https:\/\/doi.org\/10.1158\/1541-7786","journal-title":"Mol Cancer Res"},{"key":"570_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/v10050239","author":"S Kozireva","year":"2018","unstructured":"Kozireva S, Rudevica Z, Baryshev M, Leonciks A, Kashuba E, Kholodnyuk I (2018) Upregulation of the chemokine receptor CCR2B in Epstein\u2013Barr virus-positive Burkitt lymphoma cell lines with the latency III program. Viruses. https:\/\/doi.org\/10.3390\/v10050239","journal-title":"Viruses"},{"issue":"2","key":"570_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/path.4448","volume":"235","author":"SW Tsao","year":"2015","unstructured":"Tsao SW, Tsang CM, To KF, Lo KW (2015) The role of Epstein\u2013Barr virus in epithelial malignancies. J Pathol 235(2):323\u2013333. https:\/\/doi.org\/10.1002\/path.4448","journal-title":"J Pathol"},{"issue":"21","key":"570_CR18","doi-asserted-by":"publisher","first-page":"e01718","DOI":"10.1128\/JVI.01718-16","volume":"91","author":"LW Wang","year":"2017","unstructured":"Wang LW, Jiang S, Gewurz BE (2017) Epstein\u2013Barr virus LMP1-mediated oncogenicity. J Virol 91(21):e01718\u2013e01716. https:\/\/doi.org\/10.1128\/JVI.01718-16","journal-title":"J Virol"},{"issue":"10","key":"570_CR19","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1099\/0022-1317-72-10-2399","volume":"72","author":"LF Hu","year":"1991","unstructured":"Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G (1991) Isolation and sequencing of the Epstein\u2013Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72(10):2399\u20132409. https:\/\/doi.org\/10.1099\/0022-1317-72-10-2399","journal-title":"J Gen Virol"},{"key":"570_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1743-422X-11-94","volume":"11","author":"C Sueur","year":"2014","unstructured":"Sueur C, Lupo J, Mas P, Morand P, Boyer V (2014) Difference in cytokine production and cell cycle progression induced by Epstein\u2013Barr virus LMP1 deletion variants in Kmh2, a Hodgkin lymphoma cell line. Virol J 11:94. https:\/\/doi.org\/10.1186\/1743-422X-11-94","journal-title":"Virol J"},{"issue":"5","key":"570_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1084\/jem.20031255","volume":"199","author":"P Xie","year":"2004","unstructured":"Xie P, Hostager BS, Bishop GA (2004) Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocyte. J Exp Med 199(5):661\u2013671. https:\/\/doi.org\/10.1084\/jem.20031255","journal-title":"J Exp Med"},{"issue":"18","key":"570_CR22","doi-asserted-by":"publisher","first-page":"9680","DOI":"10.1128\/JVI.01001-07","volume":"81","author":"BA Mainou","year":"2007","unstructured":"Mainou BA, Everly DN Jr, Raab-Traub N (2007) Unique signaling properties of CTAR1 in LMP1-mediated transformation. J Virol 81(18):9680\u20139692. https:\/\/doi.org\/10.1128\/JVI.01001-07","journal-title":"J Virol"},{"issue":"8","key":"570_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/jmv.20896","volume":"79","author":"L Ding","year":"2007","unstructured":"Ding L, Li L, Yang J, Zhou S, Li W, Tang M et al (2007) Latent membrane protein 1 encoded by Epstein\u2013Barr virus induces telomerase activity via p16INK4A\/Rb\/E2F1 and JNK signaling pathways. J Med Virol 79(8):1153\u20131163. https:\/\/doi.org\/10.1002\/jmv.20896","journal-title":"J Med Virol"},{"issue":"13","key":"570_CR24","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/sj.onc.1201694","volume":"16","author":"AG Eliopoulos","year":"1998","unstructured":"Eliopoulos AG, Young LS (1998) Activation of the c-Jun N-terminal kinase (JNK) pathway by the Epstein\u2013Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16(13):1731\u20131742. https:\/\/doi.org\/10.1038\/sj.onc.1201694","journal-title":"Oncogene"},{"issue":"1","key":"570_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1128\/MCB.24.1.192-199.2004","volume":"24","author":"J Wan","year":"2004","unstructured":"Wan J, Sun L, Mendoza JW, Chui YL, Huang DP, Chen ZJ et al (2004) Elucidation of the c-Jun N-terminal kinase pathway mediated by Epstein\u2013Barr virus-encoded latent membrane protein 1. Mol Cell Biol 24(1): 192\u2013199. https:\/\/doi.org\/10.1128\/MCB.24.1.192-199.2004","journal-title":"Mol Cell Biol"},{"issue":"2","key":"570_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.virol.2007.09.044","volume":"371","author":"H Kutz","year":"2008","unstructured":"Kutz H, Reisbach G, Schultheiss U, Kieser A (2008) The c-Jun N-terminal kinase pathway is critical for cell transformation by the latent membrane protein 1 of Epstein\u2013Barr virus. Virology 371(2):246\u2013256. https:\/\/doi.org\/10.1016\/j.virol.2007.09.044","journal-title":"Virology"},{"issue":"16","key":"570_CR27","doi-asserted-by":"publisher","first-page":"9041","DOI":"10.1128\/JVI.00541-13","volume":"87","author":"SC Tsai","year":"2013","unstructured":"Tsai SC, Lin SJ, Lin CJ, Chou YC, Lin JH, Yeh TH et al (2013) Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein\u2013Barr virus-triggered B cell proliferation. J Virol 87(16):9041\u20139052. https:\/\/doi.org\/10.1128\/JVI.00541-13","journal-title":"J Virol"},{"issue":"6","key":"570_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1084\/jem.20080238","volume":"205","author":"C H\u00f6mig-H\u00f6lzel","year":"2008","unstructured":"H\u00f6mig-H\u00f6lzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, M\u00fcller W et al (2008) Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and promotes lymphomagenesis. J Exp Med 205(6):1317\u20131329. https:\/\/doi.org\/10.1084\/jem.20080238","journal-title":"J Exp Med"},{"issue":"5","key":"570_CR29","doi-asserted-by":"publisher","first-page":"e1004125","DOI":"10.1371\/journal.ppat.1004125","volume":"10","author":"M Siouda","year":"2014","unstructured":"Siouda M, Frecha C, Accardi R, Yue J, Cuenin C, Gruffat H et al (2014) Epstein\u2013Barr virus down-regulates tumor suppressor DOK1 expression. PLoS Pathog 10(5):e1004125. https:\/\/doi.org\/10.1371\/journal.ppat.1004125","journal-title":"PLoS Pathog"},{"issue":"3","key":"570_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/path.4201","volume":"230","author":"AK Lo","year":"2013","unstructured":"Lo AK, Lo KW, Ko CW, Young LS, Dawson CW (2013) Inhibition of the LKB1-AMPK pathway by the Epstein\u2013Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells. J Pathol 230(3):336\u2013346. https:\/\/doi.org\/10.1002\/path.4201","journal-title":"J Pathol"},{"issue":"37","key":"570_CR31","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/onc.2014.32","volume":"33","author":"L Xiao","year":"2014","unstructured":"Xiao L, Hu ZY, Dong X, Tan Z, Li W, Tang M et al (2014) Targeting Epstein\u2013Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy. Oncogene 33(37):4568\u20134578. https:\/\/doi.org\/10.1038\/onc.2014.32","journal-title":"Oncogene"},{"issue":"13","key":"570_CR32","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1182\/blood-2005-06-2341","volume":"106","author":"C Mancao","year":"2005","unstructured":"Mancao C, Altmann M, Jungnickel B, Hammerschmidt W (2005) Rescue of \u201ccrippled\u201d germinal center B cells from apoptosis by Epstein\u2013Barr virus. Blood 106(13):4339\u20134344. https:\/\/doi.org\/10.1182\/blood-2005-06-2341","journal-title":"Blood"},{"issue":"15","key":"570_CR33","doi-asserted-by":"publisher","first-page":"7612","DOI":"10.1128\/JVI.00958-15","volume":"89","author":"LR Wasil","year":"2015","unstructured":"Wasil LR, Wei L, Chang C, Lan L, Shair KH (2015) Regulation of DNA damage signaling and cell death responses by Epstein\u2013Barr virus latent membrane protein 1 (LMP1) and LMP2A in nasopharyngeal carcinoma cells. J Virol 89(15):7612\u20137624. https:\/\/doi.org\/10.1128\/JVI.00958-15","journal-title":"J Virol"},{"issue":"9","key":"570_CR34","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1128\/JVI.03714-13","volume":"88","author":"M Fukuda","year":"2014","unstructured":"Fukuda M, Kawaguchi Y (2014) Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein\u2013Barr virus LMP2A-induced cell transformation. J Virol 88(9):5189\u20135194. https:\/\/doi.org\/10.1128\/JVI.03714-13","journal-title":"J Virol"},{"key":"570_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1478-811X-10-9","volume":"10","author":"N Engels","year":"2012","unstructured":"Engels N, Yigit G, Emmerich CH, Czesnik D, Schild D, Wienands J (2012) Epstein\u2013Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal. Cell Commun Signal 10:9. https:\/\/doi.org\/10.1186\/1478-811X-10-9","journal-title":"Cell Commun Signal"},{"issue":"19","key":"570_CR36","doi-asserted-by":"publisher","first-page":"10308","DOI":"10.1128\/JVI.00853-12","volume":"86","author":"JA Fotheringham","year":"2012","unstructured":"Fotheringham JA, Coalson NE, Raab-Traub N (2012) Epstein\u2013Barr virus latent membrane protein-2A induces ITAM\/Syk- and Akt-dependent epithelial migration through \u03b1V-Integrin membrane translocation. J Virol 86(19):10308\u201310320. https:\/\/doi.org\/10.1128\/JVI.00853-12","journal-title":"J Virol"},{"issue":"17","key":"570_CR37","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1128\/JVI.00537-07","volume":"81","author":"M Fukuda","year":"2007","unstructured":"Fukuda M, Longnecker R (2007) Epstein\u2013Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras\/PI3-K\/Akt Pathway. J Virol 81(17):9299\u20139306. https:\/\/doi.org\/10.1128\/JVI.00537-07","journal-title":"J Virol"},{"issue":"4","key":"570_CR38","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1128\/JVI.78.4.1697-1705.2004","volume":"78","author":"M Fukuda","year":"2004","unstructured":"Fukuda M, Longnecker R (2004) Latent membrane protein 2A inhibits transforming growth factor-\u03b21-induced apoptosis through the phosphatidylinositol 3-kinase\/Akt pathway. J Virol 78(4):1697\u20131705. https:\/\/doi.org\/10.1128\/JVI.78.4.1697-1705.2004","journal-title":"J Virol"},{"issue":"22","key":"570_CR39","doi-asserted-by":"publisher","first-page":"10838","DOI":"10.1128\/JVI.74.22.10838-10845.2000","volume":"74","author":"R Swart","year":"2000","unstructured":"Swart R, Ruf IK, Samplev J, Longnecker R (2000) Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase\/Akt pathway. J Virol 74(22):10838\u201310845","journal-title":"J Virol"},{"issue":"10","key":"570_CR40","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1038\/leu.2010.154","volume":"24","author":"PM Bhende","year":"2010","unstructured":"Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B (2010) The dual PI3K\/mTOR inhibitor, NVP-BEZ235, is efficacious against non-Hodgkin lymphoma. Leukemia 24(10):1781\u20131784. https:\/\/doi.org\/10.1038\/leu.2010.154","journal-title":"Leukemia"},{"issue":"4","key":"570_CR41","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2013-07-517649","volume":"123","author":"K Fish","year":"2014","unstructured":"Fish K, Chen J, Longnecker R (2014) Epstein\u2013Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123(4):530\u2013540. https:\/\/doi.org\/10.1182\/blood-2013-07-517649","journal-title":"Blood"},{"issue":"23","key":"570_CR42","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2017-07-796821","volume":"130","author":"K Fish","year":"2017","unstructured":"Fish K, Sora RP, Schaller SJ, Longnecker R, Ikeda M (2017) EBV latent membrane protein 2A orchestrates p27kip1 degradation via Cks1 to accelerate MYC-driven lymphoma in mice. Blood 130(23):2516\u20132526. https:\/\/doi.org\/10.1182\/blood-2017-07-796821","journal-title":"Blood"},{"key":"570_CR43","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.virol.2016.10.015","volume":"500","author":"R Incrocci","year":"2017","unstructured":"Incrocci R, Barse L, Stone A, Vagvala S, Montesano M, Subramaniam V, Swanson-Mungerson M (2017) Epstein\u2013Barr virus latent membrane protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton\u2019s tyrosine kinase and STAT3. Virology 500:96\u2013102. https:\/\/doi.org\/10.1016\/j.virol.2016.10.015","journal-title":"Virology"},{"issue":"1","key":"570_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3892\/etm.2016.3954","volume":"13","author":"F Wang","year":"2017","unstructured":"Wang F, Chen W, Liu P, Zhou J, Liu B, Ye W, Wang W, Shen X (2017) Lentivirus-mediated RNAi knockdown of LMP2A inhibits the growth of the Epstein\u2013Barr-associated gastric carcinoma cell line GT38 in vitro. Exp Ther Med 13(1):187\u2013193. https:\/\/doi.org\/10.3892\/etm.2016.3954","journal-title":"Exp Ther Med"},{"key":"570_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040109","author":"JB Wilson","year":"2018","unstructured":"Wilson JB, Manet E, Gruffat H, Busson P, Blondel M, Fahraeus R (2018) EBNA1: oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein\u2013Barr virus-associated cancers. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers10040109","journal-title":"Cancers (Basel)"},{"issue":"8","key":"570_CR46","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1128\/MCB.5.8.1822","volume":"5","author":"D Reisman","year":"1985","unstructured":"Reisman D, Yates J, Sugden B (1985) A putative origin of replication of plasmids derived from Epstein\u2013Barr virus is composed of two cis-acting components. Mol Cell Biol 5(8):1822\u20131832. https:\/\/doi.org\/10.1128\/MCB.5.8.1822","journal-title":"Mol Cell Biol"},{"issue":"4","key":"570_CR47","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1128\/JVI.02521-13","volume":"88","author":"N Malik-Soni","year":"2014","unstructured":"Malik-Soni N, Frappier L (2014) Nucleophosmin contributes to the transcriptional activation function of the Epstein\u2013Barr virus EBNA1 protein. J Virol 88(4):2323\u20132326. https:\/\/doi.org\/10.1128\/JVI.02521-13","journal-title":"J Virol"},{"issue":"4","key":"570_CR48","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/JVI.69.4.2633-2636.1995","volume":"69","author":"T Gahn","year":"1995","unstructured":"Gahn T, Sugden B (1995) An EBNA1 dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein\u2013Barr virus LMP gene. J Virol 69(4):2633\u20132636","journal-title":"J Virol"},{"issue":"Pt 5","key":"570_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1099\/vir.0.038752-0","volume":"93","author":"C Borestr\u00f6m","year":"2012","unstructured":"Borestr\u00f6m C, Forsman A, R\u00fcetschi U, Rymo L (2012) E2F1, ARID3A\/Bright and Oct-2 factors bind to the Epstein\u2013Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions. J Gen Virol 93(Pt 5):1065\u20131075. https:\/\/doi.org\/10.1099\/vir.0.038752-0","journal-title":"J Gen Virol"},{"issue":"1","key":"570_CR50","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1128\/JVI.02318-15","volume":"90","author":"I Tempera","year":"2015","unstructured":"Tempera I, De Leo A, Kossenkov AV, Cesaroni M, Song H, Dawany N et al (2015) Identification of MEF2B, EBF1, and IL6R as direct gene targets of Epstein\u2013Barr virus (EBV) nuclear antigen 1 critical for EBV-infected B-lymphocyte survival. J Virol 90(1):345\u2013355. https:\/\/doi.org\/10.1128\/JVI.02318-15","journal-title":"J Virol"},{"issue":"5","key":"570_CR51","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1128\/JVI.73.5.4481-4484.1999","volume":"73","author":"C Kaiser","year":"1999","unstructured":"Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B (1999) The proto-oncogene c-myc is a direct target gene of Epstein\u2013Barr virus nuclear antigen 2. J Virol 73(5):4481\u20134484","journal-title":"J Virol"},{"issue":"1","key":"570_CR52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.virol.2007.12.027","volume":"374","author":"D Konforte","year":"2008","unstructured":"Konforte D, Simard N, Paige CJ (2008) Interleukin-21 regulates expression of key Epstein\u2013Barr virus oncoproteins, EBNA2 and LMPl, in infected human B cells. Virology 374(1):100\u2013113. https:\/\/doi.org\/10.1016\/j.virol.2007.12.027","journal-title":"Virology"},{"issue":"11","key":"570_CR53","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1128\/JVI.75.11.5119-5128.2001","volume":"75","author":"A Yokoyama","year":"2001","unstructured":"Yokoyama A, Tanaka M, Matsuda G, Kato K, Kanamori M, Kawasaki H et al (2001) Identification of major phosphorylation sites of Epstein\u2013Barr virus nuclear antigen leader protein (EBNA-LP): ability of EBNA-LP to induce latent membrane protein 1 cooperatively with EBNA-2 is regulated by phosphorylation. J Virol 75(11):5119\u20135128. https:\/\/doi.org\/10.1128\/JVI.75.11.5119-5128.2001","journal-title":"J Virol"},{"issue":"11","key":"570_CR54","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1128\/JVI.70.11.7885-7893.1996","volume":"70","author":"MK Kitay","year":"1996","unstructured":"Kitay MK, Rowe DT (1996) Cell cycle stage-specific phosphorylation of the Epstein\u2013Barr virus immortalization protein EBNA-LP. J Virol 70(11):7885\u20137893","journal-title":"J Virol"},{"issue":"Pt 12","key":"570_CR55","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1099\/vir.0.19454-0","volume":"84","author":"K Kato","year":"2003","unstructured":"Kato K, Yokoyama A, Tohya Y, Akashi H, Nishiyama Y, Kawaguchi Y (2003) Identification of protein kinases responsible for phosphorylation of Epstein\u2013Barr virus nuclear antigen leader protein at serine-35, which regulates its coactivator function. J Gen Virol 84(Pt 12):3381\u20133392. https:\/\/doi.org\/10.1099\/vir.0.19454-0","journal-title":"J Gen Virol"},{"issue":"23","key":"570_CR56","doi-asserted-by":"publisher","first-page":"12362","DOI":"10.1128\/JVI.06059-11","volume":"85","author":"RJ Tierney","year":"2011","unstructured":"Tierney RJ, Kao KY, Nagra JK, Rickinson AB (2011) Epstein\u2013Barr virus BamHI W repeat number limits EBNA2\/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J Virol 85(23):12362\u201312375. https:\/\/doi.org\/10.1128\/JVI.06059-11","journal-title":"J Virol"},{"issue":"2","key":"570_CR57","doi-asserted-by":"publisher","first-page":"e1006890","DOI":"10.1371\/journal.ppat.1006890","volume":"14","author":"A Szymula","year":"2018","unstructured":"Szymula A, Palermo RD, Bayoumy A, Groves IJ, Ba Abdullah M et al (2018) Epstein\u2013Barr virus nuclear antigen EBNA-LP is essential for transforming na\u00efve B cells, and facilitates recruitment of transcription factors to the viral genome. PLoS Pathog 14(2):e1006890. https:\/\/doi.org\/10.1371\/journal.ppat.1006890","journal-title":"PLoS Pathog"},{"key":"570_CR58","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01918-17","author":"Q Bazot","year":"2018","unstructured":"Bazot Q, Paschos K, Allday MJ (2018) Epstein\u2013Barr virus (EBV) latent protein EBNA3A directly targets and silences the STK39 gene in B cells infected by EBV. J Virol. https:\/\/doi.org\/10.1128\/JVI.01918-17","journal-title":"J Virol"},{"issue":"10","key":"570_CR59","doi-asserted-by":"publisher","first-page":"e1004415","DOI":"10.1371\/journal.ppat.1004415","volume":"10","author":"ML Tursiella","year":"2014","unstructured":"Tursiella ML, Bowman ER, Wanzeck KC, Throm RE, Liao J, Zhu J, Sample CE (2014) Epstein\u2013Barr virus nuclear antigen 3A promotes cellular proliferation by repression of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1. PLoS Pathog 10(10):e1004415. https:\/\/doi.org\/10.1371\/journal.ppat.1004415","journal-title":"PLoS Pathog"},{"issue":"15","key":"570_CR60","doi-asserted-by":"publisher","first-page":"9700","DOI":"10.1093\/nar\/gku697","volume":"42","author":"Q Bazot","year":"2014","unstructured":"Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML et al (2014) Epstein\u2013Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res 42(15):9700\u20139716. https:\/\/doi.org\/10.1093\/nar\/gku697","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"570_CR61","doi-asserted-by":"publisher","first-page":"e1000951","DOI":"10.1371\/journal.ppat.1000951","volume":"6","author":"L Skalska","year":"2010","unstructured":"Skalska L, White RE, Franz M, Ruhmann M, Allday MJ (2010) Epigenetic repression of p16 (INK4A) by latent Epstein\u2013Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6(6):e1000951. https:\/\/doi.org\/10.1371\/journal.ppat.1000951","journal-title":"PLoS Pathog"},{"issue":"8","key":"570_CR62","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1128\/JVI.02500-07","volume":"82","author":"BG Bajaj","year":"2008","unstructured":"Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, Robertson ES (2008) Epstein\u2013Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82(8):4082\u20134090. https:\/\/doi.org\/10.1128\/JVI.02500-07","journal-title":"J Virol"},{"issue":"14","key":"570_CR63","doi-asserted-by":"publisher","first-page":"18116","DOI":"10.18632\/oncotarget.7502","volume":"7","author":"SK Shukla","year":"2016","unstructured":"Shukla SK, Jha HC, El-Naccache DW, Robertson ES (2016) An EBV recombinant deleted for residues 130\u2013159 in EBNA3C can deregulate p53\/Mdm2 and Cyclin D1\/CDK6 which results in apoptosis and reduced cell proliferation. Oncotarget 7(14):18116\u201318134. https:\/\/doi.org\/10.18632\/oncotarget.7502","journal-title":"Oncotarget"},{"issue":"7","key":"570_CR64","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.yexcr.2006.01.020","volume":"312","author":"M Russell","year":"2006","unstructured":"Russell M, Berardi P, Gong W, Riabowol K (2006) Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 312(7):951\u2013961. https:\/\/doi.org\/10.1016\/j.yexcr.2006.01.020","journal-title":"Exp Cell Res"},{"issue":"11","key":"570_CR65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.tibs.2007.08.006","volume":"32","author":"MA Soliman","year":"2007","unstructured":"Soliman MA, Riabowol K (2007) After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci 32(11):509\u2013519. https:\/\/doi.org\/10.1016\/j.tibs.2007.08.006","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"570_CR66","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1128\/JVI.02279-10","volume":"85","author":"A Saha","year":"2011","unstructured":"Saha A, Bamidele A, Murakami M, Robertson ES (2011) EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85(5): 2079\u20132088. https:\/\/doi.org\/10.1128\/JVI.02279-10","journal-title":"J Virol"},{"key":"570_CR67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.virol.2013.10.023","volume":"448","author":"SK Sahu","year":"2014","unstructured":"Sahu SK, Mohanty S, Kumar A, Kundu CN, Verma SC, Choudhuri T (2014) Epstein\u2013Barr virus nuclear antigen 3C interact with p73: Interplay between a viral oncoprotein and cellular tumor suppressor. Virology 448:333\u2013343. https:\/\/doi.org\/10.1016\/j.virol.2013.10.023","journal-title":"Virology"},{"issue":"6444","key":"570_CR68","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/365349a0","volume":"365","author":"DG Johnson","year":"1993","unstructured":"Johnson DG, Schwarz JK, Cress WD, Nevins JR (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365(6444):349\u2013352. https:\/\/doi.org\/10.1038\/365349a0","journal-title":"Nature"},{"issue":"4\u20135","key":"570_CR69","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drup.2010.06.001","volume":"13","author":"D Engelmann","year":"2010","unstructured":"Engelmann D, P\u00fctzer BM (2010) Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance. Drug Resist Updat 13(4\u20135):119\u2013131. https:\/\/doi.org\/10.1016\/j.drup.2010.06.001","journal-title":"Drug Resist Updat"},{"issue":"3","key":"570_CR70","doi-asserted-by":"publisher","first-page":"e1002573","DOI":"10.1371\/journal.ppat.1002573","volume":"8","author":"A Saha","year":"2012","unstructured":"Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES (2012) E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog 8(3):e1002573. https:\/\/doi.org\/10.1371\/journal.ppat.1002573","journal-title":"PLoS Pathog"},{"issue":"8","key":"570_CR71","doi-asserted-by":"publisher","first-page":"e1005844","DOI":"10.1371\/journal.ppat.1005844","volume":"12","author":"Y Pei","year":"2016","unstructured":"Pei Y, Banerjee S, Sun Z, Jha HC, Saha A, Robertson ES (2016) EBV nuclear antigen 3C mediates regulation of E2F6 to inhibit E2F1 transcription and promote cell proliferation. PLoS Pathog 12(8):e1005844. https:\/\/doi.org\/10.1371\/journal.ppat.1005844","journal-title":"PLoS Pathog"},{"issue":"5","key":"570_CR72","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1073\/pnas.1019599108","volume":"108","author":"S Maruo","year":"2011","unstructured":"Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K (2011) Epstein\u2013Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108(5):1919\u20131924. https:\/\/doi.org\/10.1073\/pnas.1019599108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"570_CR73","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1128\/JVI.01302-06","volume":"81","author":"M Rovedo","year":"2007","unstructured":"Rovedo M, Longnecker R (2007) Epstein\u2013Barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 81(1):84\u201394. https:\/\/doi.org\/10.1128\/JVI.01302-06","journal-title":"J Virol"},{"issue":"4","key":"570_CR74","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1172\/JCI58092","volume":"122","author":"RE White","year":"2012","unstructured":"White RE, R\u00e4mer PC, Naresh KN, Meixlsperger S, Pinaud L et al (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122(4):1487\u20131502. https:\/\/doi.org\/10.1172\/JCI58092","journal-title":"J Clin Invest"},{"key":"570_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","volume":"66","author":"M Naseem","year":"2018","unstructured":"Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R et al (2018) Outlooks on Epstein\u2013Barr virus associated gastric cancer. Cancer Treat Rev 66:15\u201322. https:\/\/doi.org\/10.1016\/j.ctrv.2018.03.006","journal-title":"Cancer Treat Rev"},{"key":"570_CR76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.4459","volume":"235","author":"M Vockerodt","year":"2015","unstructured":"Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG (2015) The Epstein\u2013Barr virus and the pathogenesis of lymphoma. J Pathol 235:312\u2013322. https:\/\/doi.org\/10.1002\/path.4459","journal-title":"J Pathol"},{"issue":"12","key":"570_CR77","doi-asserted-by":"publisher","first-page":"581","DOI":"10.5732\/cjc.014.10197","volume":"33","author":"LS Young","year":"2014","unstructured":"Young LS, Dawson CW (2014) Epstein\u2013Barr virus and nasopharyngeal carcinoma. Chin J Cancer 33(12):581\u2013590. https:\/\/doi.org\/10.5732\/cjc.014.10197","journal-title":"Chin J Cancer"},{"issue":"1","key":"570_CR78","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/tbj.12828","volume":"24","author":"T Pai","year":"2018","unstructured":"Pai T, Gupta S, Gurav M, Nag S, Shet T, Patil A, Desai S (2018) Evidence for the association of Epstein\u2013Barr virus in breast cancer in Indian patients using in-situ hybridization technique. Breast J 24(1):16\u201322. https:\/\/doi.org\/10.1111\/tbj.12828","journal-title":"Breast J"},{"issue":"1","key":"570_CR79","doi-asserted-by":"publisher","first-page":"e01926-15","DOI":"10.1128\/mBio.01926-15","volume":"7","author":"KM Herbert","year":"2016","unstructured":"Herbert KM, Pimienta (2016) Consideration of Epstein\u2013Barr virus-encoded noncoding RNAs EBER1 and EBER2 as a functional backup of viral oncoprotein latent membrane protein 1. MBio 7(1):e01926-15. https:\/\/doi.org\/10.1128\/mBio.01926-15","journal-title":"MBio"},{"issue":"12","key":"570_CR80","doi-asserted-by":"crossref","first-page":"9827","DOI":"10.1128\/JVI.73.12.9827-9831.1999","volume":"73","author":"J Komano","year":"1999","unstructured":"Komano J, Maruo S, Kurozumi K, Oda T, Takada K (1999) Oncogenic role of Epstein\u2013Barr virus-encoded RNAs in Burkitt\u2019s lymphoma cell line Akata. J Virol 73(12):9827\u20139831","journal-title":"J Virol"},{"issue":"3","key":"570_CR81","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/j.1600-0609.2005.00498.x","volume":"75","author":"M Kobayashi","year":"2005","unstructured":"Kobayashi M, Nakamura S, Shibata K, Sahara N, Shigeno K, Shinjo K et al (2005) Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt\u2019s lymphoma cells. Eur J Haematol 75(3):212\u2013220. https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00498.x","journal-title":"Eur J Haematol"},{"issue":"2","key":"570_CR82","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0014-5793(00)02145-1","volume":"484","author":"N Yamamoto","year":"2000","unstructured":"Yamamoto N, Takizawa T, Iwanaga Y, Shimizu N, Yamamoto N (2000) Malignant transformation of B lymphoma cell line BJAB by Epstein\u2013Barr virus-encoded small RNAs. FEBS Lett 484(2):153\u2013158. https:\/\/doi.org\/10.1016\/S0014-5793(00)02145-1","journal-title":"FEBS Lett"},{"issue":"2","key":"570_CR83","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.virol.2013.05.020","volume":"443","author":"AS Banerjee","year":"2013","unstructured":"Banerjee AS, Pal AD, Banerjee S (2013) Epstein\u2013Barr virus-encoded small non-coding RNAs induce cancer cell chemoresistance and migration. Virology 443(2):294\u2013305. https:\/\/doi.org\/10.1016\/j.virol.2013.05.020","journal-title":"Virology"},{"issue":"5671","key":"570_CR84","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.1096781","volume":"304","author":"S Pfeffer","year":"2004","unstructured":"Pfeffer S, Zavolan M, Gr\u00e4sser FA, Chien M, Russo JJ, Ju J et al (2004) Identification of virus-encoded microRNAs. Science 304(5671):734\u2013736. https:\/\/doi.org\/10.1126\/science.1096781","journal-title":"Science"},{"key":"570_CR85","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jbiotec.2015.06.379","volume":"209","author":"E Mili\u00e1n","year":"2015","unstructured":"Mili\u00e1n E, Prats E, Cair\u00f3 JJ, G\u00f2dia F, Vives J (2015) BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas. J Biotechnol 209:58\u201367. https:\/\/doi.org\/10.1016\/j.jbiotec.2015.06.379","journal-title":"J Biotechnol"},{"issue":"2","key":"570_CR86","doi-asserted-by":"publisher","first-page":"e1001294","DOI":"10.1371\/journal.ppat.1001294","volume":"7","author":"R Feederle","year":"2011","unstructured":"Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, Cullen BR, Delecluse HJ (2011) A viral microRNA cluster strongly potentiates the transforming properties of a human herpesvirus. PLoS Pathog 7(2):e1001294. https:\/\/doi.org\/10.1371\/journal.ppat.1001294","journal-title":"PLoS Pathog"},{"issue":"3","key":"570_CR87","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/leu.2015.285","volume":"30","author":"J Ma","year":"2016","unstructured":"Ma J, Nie K, Redmond D, Liu Y, Elemento O, Knowles DM, Tam W (2016) EBV-miR-BHRF1-2 targets PRDM1\/Blimp1: potential role in EBV lymphomagenesis. Leukemia 30(3):594\u2013604. https:\/\/doi.org\/10.1038\/leu.2015.285","journal-title":"Leukemia"},{"issue":"11","key":"570_CR88","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1593\/neo.09888","volume":"11","author":"RW Lung","year":"2009","unstructured":"Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL et al (2009) Modulation of LMP2A expression by a newly identified Epstein\u2013Barr virus-encoded microRNA miR-BART22. Neoplasia 11(11):1174\u20131184","journal-title":"Neoplasia"},{"issue":"1","key":"570_CR89","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ijc.28007","volume":"133","author":"T Lei","year":"2013","unstructured":"Lei T, Yuen KS, Xu R, Tsao SW, Chen H, Li M et al (2013) Targeting of DICE1 tumor suppressor by Epstein\u2013Barr virus-encoded miR-BART3* microRNA in nasopharyngeal carcinoma. Int J Cancer 133(1):79\u201387. https:\/\/doi.org\/10.1002\/ijc.28007","journal-title":"Int J Cancer"},{"issue":"6","key":"570_CR90","doi-asserted-by":"publisher","first-page":"e1004979","DOI":"10.1371\/journal.ppat.1004979","volume":"11","author":"D Kang","year":"2015","unstructured":"Kang D, Skalsky RL, Cullen BR (2015) EBV BART microRNAs target multiple pro-apoptotic cellular genes to promote epithelial cell survival. PLoS Pathog 11(6):e1004979. https:\/\/doi.org\/10.1371\/journal.ppat.1004979","journal-title":"PLoS Pathog"},{"issue":"6","key":"570_CR91","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1159\/000479749","volume":"9","author":"Y Lu","year":"2017","unstructured":"Lu Y, Qin Z, Wang J, Zheng X, Lu J, Zhang X, Wei L et al (2017) Epstein\u2013Barr virus miR-BART6-3p inhibits the RIG-I pathway. J Innate Immun 9(6):574\u2013586. https:\/\/doi.org\/10.1159\/000479749","journal-title":"J Innate Immun"},{"issue":"3","key":"570_CR92","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/cncr.26309","volume":"118","author":"AM Wong","year":"2012","unstructured":"Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY (2012) Profiling of Epstein\u2013Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 118(3):698\u2013710. https:\/\/doi.org\/10.1002\/cncr.26309","journal-title":"Cancer"},{"issue":"10","key":"570_CR93","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/jmv.24863","volume":"89","author":"Z Zhao","year":"2017","unstructured":"Zhao Z, Liu W, Liu J, Wang J, Luo B (2017) The effect of EBV on WIF1, NLK, and APC gene methylation and expression in gastric carcinoma and nasopharyngeal cancer. J Med Virol 89(10):1844\u20131851. https:\/\/doi.org\/10.1002\/jmv.24863","journal-title":"J Med Virol"},{"key":"570_CR94","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.12659\/MSM.897306","volume":"22","author":"L Zhou","year":"2016","unstructured":"Zhou L, Bu Y, Liang Y, Zhang F, Zhang H, Li S (2016) Epstein\u2013Barr virus (EBV)-BamHI-A rightward transcript (BART)-6 and cellular microRNA-142 synergistically compromise immune defense of host cells in EBV-positive Burkitt lymphoma. Med Sci Monit 22:4114\u20134120. https:\/\/doi.org\/10.12659\/MSM.897306","journal-title":"Med Sci Monit"},{"issue":"10","key":"570_CR95","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/onc.2013.71","volume":"33","author":"DT Vereide","year":"2014","unstructured":"Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A et al (2014) Epstein\u2013Barr virus maintains lymphomas via its miRNAs. Oncogene 33(10):1258\u20131264. https:\/\/doi.org\/10.1038\/onc.2013.71","journal-title":"Oncogene"},{"issue":"1","key":"570_CR96","doi-asserted-by":"publisher","first-page":"e1004561","DOI":"10.1371\/journal.ppat.1004561","volume":"11","author":"J Qiu","year":"2015","unstructured":"Qiu J, Smith P, Leahy L, Thorley-Lawson DA (2015) The Epstein\u2013Barr virus encoded BART miRNAs potentiate tumor growth in vivo. PLoS Pathog 11(1), e1004561. https:\/\/doi.org\/10.1371\/journal.ppat.1004561","journal-title":"PLoS Pathog"},{"issue":"10","key":"570_CR97","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.4049\/jimmunol.1501605","volume":"198","author":"MJG Hooykaas","year":"2017","unstructured":"Hooykaas MJG, van Gent M, Soppe JA, Kruse E, Boer IGJ, van Leenen D et al (2017) EBV microRNA BART16 suppresses type I IFN signaling. J Immunol 198(10):4062\u20134073. https:\/\/doi.org\/10.4049\/jimmunol.1501605","journal-title":"J Immunol"},{"issue":"4","key":"570_CR98","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/path.5018","volume":"244","author":"RW Lung","year":"2018","unstructured":"Lung RW, Hau PM, Yu KH, Yip KY, Tong JH, Chak WP et al (2018) EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma. J Pathol 244(4):394\u2013407. https:\/\/doi.org\/10.1002\/path.5018","journal-title":"J Pathol"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-018-0570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00430-018-0570-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-018-0570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T12:40:29Z","timestamp":1605357629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-018-0570-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["570"],"URL":"https:\/\/doi.org\/10.1007\/s00430-018-0570-1","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]},"assertion":[{"value":"24 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that the research was conducted in the absence of any financial or non-financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}